Follow KDKA-TV: Facebook | Twitter
PITTSBURGH (KDKA) — The Food and Drug Administration has a new warning and recall about two thyroid medications made by a Chinese manufacturer.
AdChoices
ADVERTISING
The FDA has issued a voluntary recall for the medications because of potential problems with an ingredient in them.
The warning was issued Aug. 9 for Levothyroxine and Liothyronine 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg thyroid tablets.
In the statement, the FDA says the medications were “manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s import alert.”
The FDA says those ingredients were found to have deficiencies.
“Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product,” they warn.
For more information on the recall, visit FDA.gov.

AD 00:09 / 00:15 Quality Auto360p720p1080p
SPONSORED CONTENT
Nikolaj Coster-Waldau
Nikolaj Coster-Waldau Cover
Promoted by Hearst

Company Announcement
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.
Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

•For Immediate Release
August 9, 2018
Contact
Consumers
Jonathan H. Olive
recalls@wprx.com
888-354-9939
Announcement
Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Manufacturing Practices (cGMP). Substandard cGMP practices could represent the possibility of risk being introduced into the manufacturing process.
To date, Westminster Pharmaceuticals has not received any reports of adverse events related to this product.
Levothyroxine and Liothyronine (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. Thyroid tablets contain both tetraiodothyronine sodium (T4 levothyroxine) and liothyronine sodium (T3 liothyronine). Levothyroxine and Liothyronine tablets (thyroid tablets, USP) are indicated as replacement or supplemental therapy in patients with hypothyroidism. Appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. Thyroid is not associated with serious adverse reactions and does not have a known tumorigenic potential.
Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product.
The products subject to recall are packed in 100-count bottles. To best identify the product the NDC’s, Product Description, Lot numbers and Expiration dates are listed below. These lots were distributed nationwide in the USA to Westminster’s direct accounts.
NDC Product Lot Expiration
69367-159-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15mg X 100ct 15918VP03 2/29/2020
15918VP02 2/29/2020
15918VP01 2/29/2020
15918007 3/31/2020
15918006 3/31/2020
15918005 2/29/2020
15918004 12/31/2019
15918003 12/31/2019
15918002 12/31/2019
15918001 12/31/2019
15917VP03 10/31/2019
15917VP02 10/31/2019
15917VP01 10/31/2019
69367-155-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 30mg X 100ct 15517VP01 8/31/2019
15517VP02 8/31/2019
15517VP03 8/31/2019
15518001 12/31/2019
15518002 3/31/2020
69367-156-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 60mg X 100ct 15618011 3/31/2020
15618009 2/29/2020
15618008 2/29/2020
15618004 12/31/2019
15618002 12/31/2019
15617VP06 11/30/2019
15617VP05 11/30/2019
15617VP04 12/31/2019
15617VP03 7/31/2019
15617VP01 7/31/2019
15617VP-02 7/31/2019
69367-157-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 90mg X 100ct 15717VP-01 7/31/2019
15717VP-02 7/31/2019
15717VP-03 7/31/2019
15718004 3/31/2020
15717002 12/31/2019
69367-158-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 120mg X 100ct 15817VP-01 9/30/2019
15817VP-02 9/30/2019
15817VP-03 9/30/2019
15818001 3/31/2020
Westminster is notifying its direct accounts by email and by phone to immediately discontinue distribution of the product being recalled and to notify their sub-wholesale accounts of this product recall and make arrangements for impacted product to be returned to Westminster. Instructions for returning recalled products are given in the Recall Notice Letter and Recall Response Form. Consumers that have these products which are being recalled should not discontinue use before contacting their physician for further guidance.
Customers and patients with medical-related questions, information about an adverse event or other questions about the Westminster’s product’s being recalled should contact Westminster’s Regulatory Affairs department by phone at: 888-354-9939
• Live calls are received Monday-Friday, 9:00AM - 5:00PM EST with voicemail available 24 hours/day, 7 days/week or email recalls@wprx.com.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
• Complete and submit the report Online: www.fda.gov/medwatch/report.htm
• Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA- 0178

###
Follow FDA
• Follow @US_FDA on Twitter
• Follow FDA on Facebook
• Follow @FDArecalls on Twitter
• Recent Recalled Product Photos on FDA's Flickr Photostream

More in Recalls, Market Withdrawals, & Safety Alerts

Archive for Recalls, Market Withdrawals & Safety Alerts
Enforcement Reports
Pending RecallsArchived Enforcement ReportsIndustry Guidance
Major Product Recalls
McCain Foods Product RecallsVegetable/Produce Recalls Associated with Mann Packing (Listeria monocytogenes)DKH Cheese Recalls (Listeria monocytogenes contamination)2016 Frozen vegetable products (Listeria monocytogenes)Industry Resources for RecallsUndeclared Peanut (from Cumin Ingredient) RecallsSunland Nut and Seed Product RecallsPage Last Updated: 08/10/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English

Home Health News Pregnant women took generic Viagra in a clinical drug trial. Eleven babies died.
HEALTH NEWS
Pregnant women took generic Viagra in a clinical drug trial. Eleven babies died.
By admin
Posted on July 25, 2018
7 min read
0
69

(iStock)
by Cleve R. Wootson Jr. July 25 at 5:11 PM Email the author
Dutch doctors were trying to answer a simple question about a popular drug: Could the active ingredient in Viagra be used to help a particular group of at-risk babies often born tiny and premature with slim chances of survival?
The study had already been conducted in New Zealand and Australia, according to Amsterdam Universitair Medische Centra (University Medical Center), which headed the latest trial. The Dutch component involved some 183 pregnant women who suffered from fetal growth restriction, where an underdeveloped placenta can’t get enough oxygen or nutrients to a gestating baby.
Sildenafil, a generic version of the erectile dysfunction drug Viagra, was given to 93 pregnant women; another 90 were given an inert placebo. Doctors across 11 hospitals planned to study the mothers and their children through 2020.
Then the babies started dying.
After they were born, 11 of the babies whose mothers had been given sildenafil developed a form of high blood pressure in the lungs, which killed them, the researchers said. Six babies in that group also suffered the complication but survived.
In the placebo group, three developed the disorder, but all of them survived.
“The chance of a disease of the blood vessels of the lungs appears to be greater and the chance of death after birth seems to have increased,” Amsterdam UMC said in a release.
And there were “no positive effects for the children on other outcomes,” the researchers concluded. “All adverse effects occurred after birth. . . . Based on these findings, the study stopped immediately.”
Doctors conceded they had more questions than answers: What about the drug had caused the babies to die? Why were there no similar problems for babies in the previous studies?
In a statement, Pfizer, the maker of Viagra, expressed its “sympathy for the trial participants and their families” but said the company had nothing to do with the trial.
[Watch the moment drivers stopped to rescue an infant abandoned on a freezing street]
“Pfizer was not involved in any aspect of this trial, and neither funded nor provided product for the trial,” the statement said. “In addition, the Principle Investigators at the Amsterdam University Medical Centre have confirmed a non-Pfizer manufactured generic version of sildenafil was used but that no clinical trial participants were administered Viagra, Pfizer sildenafil or any other Pfizer medicine.”
The company asserted that “the safety and efficacy of Viagra has been well documented in clinical studies.”
Researchers said their principle goal now is to find out what happened.
Doctors intend to “extensively” analyze all the data they’ve been able to collect so far, and “the development of the children will be closely monitored.”
“This finding in the Dutch study is unexpected,” Zarko Alfirevic, a professor at the University of Liverpool and one of the authors cited in a similar United Kingdom study, told the BBC. “We need to be careful at this point to find out more. It needs a thorough investigation because the complications were not seen in the two other, similar trials that have already been done in the U.K. and Australia and New Zealand.”
Intrauterine growth restriction occurs when some problem or abnormality prevents a fetus’s cells from growing or makes cells decrease in size, according to Stanford Children’s Health.
More than a dozen things can cause intrauterine growth restriction, including maternal diseases like diabetes or high blood pressure, chromosomal abnormalities in the baby or several types of infection.
Affected babies can be stillborn or have long-term growth problems that last well into childhood.
There is no known cure.
Read more:
The risky surgery to remove a woman’s 132-pound tumor that grew by 10 pounds every week
A boy’s basketball-size tumor was slowly killing him. He died days after doctors removed it.
A gunshot destroyed her face. A rare surgery just gave her a new one.
Teen camper wakes up to ‘crunching noise’ — and discovers his head is inside bear’s mouth
A woman with a transplanted uterus just gave birth — a first for the U.S.

Viagra goes generic: Pfizer to launch own little white pill
Posted: 11:30 AM, Dec 06, 2017
Updated: 12:30 PM, Dec 06, 2017
By: Associated Press

The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first generic competition.
On Monday, Pfizer will begin selling the generic at half the $65-a-pill retail price. Generic maker Teva Pharmaceuticals can start selling its version then, but isn't disclosing the price.
Many more generics go on sale next summer, which will steadily slash the price of generics, possibly by 90 percent.
Launched in 1998, Viagra was the first pill for impotence. Cialis and Levitra, which came out in 2003, get their own generic competition next fall.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Viagra Linked to 522 Deaths
By Jeff Levine
Share on FacebookShare on TwitterShare on PinterestSaveEmailPrint
From the WebMD Archives
March 14, 2000 (Anaheim, Calif.) -- New research shows that 522 patients have died while taking Viagra (sildenafil) in the first year the drug was on the market. Since its introduction in March of 1998, more than 12 million prescriptions of the blockbuster treatment for erectile dysfunction (ED) have been written. There are continued concerns that the drug could trigger heart problems in some users; already it is not recommended for patients taking nitrates for this reason.
"Our data appear to suggest that there's a relatively high number of deaths and adverse cardiovascular events associated with the use of Viagra. I want to emphasize that in no way are we trying to imply a cause-and-effect relationship," lead researcher Sanjay Kaul, MD, a critical care cardiologist at Cedars-Sinai Medical Center in Los Angeles, tells WebMD. Kaul presented his findings here Tuesday at the 49th Annual Scientific Session of the American College of Cardiology.
Kaul got his numbers by lodging a Freedom of Information Act request with the FDA. Overall, he found 1,473 major adverse events in the agency's surveillance database related to Viagra. For instance, in addition to the 522 deaths, Kaul noted 517 patients who experienced heart attack or anginal chest pain when using the drug.
However, it's difficult to interpret the data without comparing them to a similar population not taking the drug, and that's why Kaul says that additional research is necessary. In the meantime, he says there's no reason to panic.

Continue Reading Below
you might like
"The most important message is that in most patients at low risk, Viagra is generally safe. However, you need to evaluate the patient's cardiac risk before you prescribe Viagra," says Kaul.
Meanwhile, another Viagra study presented here Tuesday came to a very different conclusion. This research, done in collaboration with Pfizer, Viagra's manufacturer, compared some 4,500 patients taking the drug to about 3,100 on placebo. The bottom line is that the rates of heart attack and death in men with ED treated with Viagra were low, and there wasn't any real difference between the groups.
"It's reassuring that ... in general, for most patients, even those with existing coronary [heart] disease ... resuming sexual activity is very unlikely to trigger a [coronary] event," says lead researcher Murray A. Mittleman, MD, an internist and preventive cardiologist at Beth Israel Deaconess Medical Center in Boston.
Mittleman says that the FDA database is better at spotting unusual events than seeing aberrations in common conditions like heart attacks. However, the agency concedes that drug problems are drastically underreported, with perhaps only one in 10 eventually getting the FDA's attention.
WebMD Health News
© 2000 WebMD, Inc. All rights reserved.

Will you have Sudden death with Viagra - from FDA reports

Summary
Sudden death is found among people who take Viagra, especially for people who are male, 60+ old , have been taking the drug for < 1 month, also take medication Tracleer, and have Primary pulmonary hypertension. This study is created by eHealthMe based on reports of 52,549 people who have side effects when taking Viagra from FDA, and is updated regularly.
________________________________________
________________________________________
What's eHealthMe?
eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.
eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.
How we gather our data?
Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.
The information that eHealthMe collects includes:
• Side effects (including severity and how people recover from them)
• Associated conditions or symptoms
• Drug effectiveness
• Demographic data regarding drug use
How the study uses the data?
The study is based on sildenafil citrate (the active ingredients of Viagra) and Viagra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Synonyms of Sudden death are also considered in the study.
What is Viagra?
Viagra has active ingredients of sildenafil citrate. It is often used in erection problems. (latest outcomes from Viagra 54,340 users)
What is Sudden death?
Sudden death has been reported by people with multiple myeloma, primary pulmonary hypertension, pain, chronic myeloid leukaemia, diabetes (latest reports from 484,550 Sudden death patients).
How to use the study?
Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.
________________________________________
On Feb, 23, 2019
52,549 people reported to have side effects when taking Viagra.
Among them, 1,340 people (2.55%) have Sudden death
________________________________________
Number of reports submitted per year:

Time on Viagra when people have Sudden death *:
• < 1 month: 29.33 %
• 1 - 6 months: 17.33 %
• 6 - 12 months: 8.0 %
• 1 - 2 years: 6.67 %
• 2 - 5 years: 25.33 %
• 5 - 10 years: 9.33 %
• 10+ years: 4.0 %
Gender of people who have Sudden death when taking Viagra *:
• female: 8.47 %
• male: 91.53 %
Age of people who have Sudden death when taking Viagra *:
• 0-1: 0.65 %
• 2-9: 0.48 %
• 10-19: 0.32 %
• 20-29: 1.78 %
• 30-39: 4.36 %
• 40-49: 10.02 %
• 50-59: 25.2 %
• 60+: 57.19 %
Top conditions involved for these people *:
1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 124 people, 9.25%
2. Ill-Defined Disorder: 44 people, 3.28%
3. Pulmonary Hypertension (increase in blood pressure in the lung artery): 38 people, 2.84%
4. High Blood Pressure: 21 people, 1.57%
5. Multiple Myeloma (cancer of the plasma cells): 17 people, 1.27%
6. Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 12 people, 0.90%
7. Pain: 12 people, 0.90%
8. Prostate Cancer: 11 people, 0.82%
9. Coronary Artery Bypass: 9 people, 0.67%
10. Metastases To Bone (cancer spreads to bone): 8 people, 0.60%
Top co-used drugs for these people *:
1. Tracleer: 78 people, 5.82%
2. Lasix: 56 people, 4.18%
3. Coumadin: 46 people, 3.43%
4. Lipitor: 44 people, 3.28%
5. Letairis: 38 people, 2.84%
6. Digoxin: 37 people, 2.76%
7. Prednisone: 37 people, 2.76%
8. Lisinopril: 35 people, 2.61%
9. Norvasc: 34 people, 2.54%
10. Nitroglycerin: 33 people, 2.46%
Top other side effects for these people *:
1. Pain: 47 people, 3.51%
2. Stress And Anxiety: 46 people, 3.43%
3. Breathing Difficulty: 40 people, 2.99%
4. Malignant Melanoma (skin cancer rises from melancytes): 33 people, 2.46%
5. Heart Attack: 33 people, 2.46%
6. Weakness: 33 people, 2.46%
7. Fatigue (feeling of tiredness): 30 people, 2.24%
8. Acute Kidney Failure: 29 people, 2.16%
9. Fainting (loss of consciousness and postural tone): 28 people, 2.09%
10. Injury: 26 people, 1.94%
* Approximation only. Some reports may have incomplete information.
Do you have Sudden death while taking Viagra?
• Check whether a drug or a condition causes Sudden death
• Subscribe to monitor Sudden death in Viagra
________________________________________
You are not alone:
• Connect with people like you who take Viagra and have Sudden death
• Use your healthcare experience to help people like you, and be rewarded

________________________________________
________________________________________
Related publications that referenced our studies
• Jeong SY, Jeon SJ, Kim YR, Choi SS, Kwak HS, "A Rare Case of Viagra Induced Toxic Encephalopathy", Investigative Magnetic Resonance Imaging, 2016 Sep .
Related studies
Drugs that are associated with Sudden death
Sudden death (3,547 drugs)
Could your condition cause Sudden death
Sudden death (3,584 conditions)
Viagra side effects
• Viagra side effects (52,559 reports)

Browse side effects by gender and age
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Viagra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
________________________________________
________________________________________
What would happen?
Predict new side effects and undetected conditions when you take Viagra and have Sudden death
________________________________________
________________________________________
FDA reports used in this study
• Want to find out more about the FDA reports used in the study? You can request them from FDA.

Full List of All Levothyroxine Recalls, FDA 2012-2017

Posted on June 19, 2017
Share Facebook Twitter LinkedIn Email
To date there have been 12 major recalls of Levothyroxine, amounting to 2.7 million bottles. The biggest was from King Legacy in 2013 for 1.18 million bottles. The most recent was a 2017 recall that affected just 90 capsules.
Finding info on a certain Levothyroxine recall can be tough. Below, we’ve simplified all data on the recalls of this popular generic, including numbers of bottles, dates, manufacturers, lot numbers, and reasons behind the recall.
Levothyroxine Recalls
There have been 99 total recall orders of Levothyroxine from 2012 through 2017. That’s a lot of recalls for a single generic in five years. However, the vast majority of those are actually multiple orders stemming from a few events.
For example, 11 recalls in 2015 all happened on the same date against Quality Animal Care. The stated reason was an FDA inspection that revealed poor manufacturing practices. So, this is really just one big recall with 11 different recall orders for different dosage sizes.
There are 12 major recalls of that nature, with 12 minor, single-order recalls. By that classification, there have really only been 24 distinct recalls of the popular generic. All together, they affected over 2.7 million bottles.
The top-line view of all the recalls is shown in the table below.

Levothyroxine Manufacturer Recall Year Number of Bottles
Quality Animal Care Mfg 2015 210,000
Virbac AH 2015 10,000
Aidapak Services 2014 3,200
Lloyd Inc. of Iowa 2013 430,000
King Legacy (Pfizer) 2013 1,180,000
Lloyd Inc. of Iowa 2013 126,000
Pfizer 2013 250,000
Lloyd Inc. of Iowa 2012 54,000
Lloyd Inc. of Iowa 2012 140,000
Lloyd Inc. of Iowa 2012 17,000
Abbott Laboratories 2012 136,000
Lloyd Inc. of Iowa 2012 38,000
Other (small recalls) 146,000
Total Bottles Recalled 2,740,200
Levothyroxine Facts
Via: NIH.gov
Levothyroxine is a popular generic thyroid medication that replaces a hormone made by the thyroid gland to regulate metabolism and energy level. It’s used to treat people whose thyroid glands have stop making enough.
Serious side effects of Levothyroxine include chest pain, irregular or fast heart rate, fever, sweating, weakness, memory problems, vomiting, and weight changes. More common side effects are leg cramps, headache, diarrhea, and skin rashes.
Also see our full Lisinopril facts article here.Lisinopril facts article here.
Major Levothyroxine Recalls
Aside from the small, one-off events involving only a few hundred or a few thousand bottles each, there have been 12 major Levothyroxine recalls from 2012 through 2017. These recalls involved a total of 2.72 million bottles of the drug.
Most of the big recalls can be seen in the table above. They’re made up of several recall orders each.
The one exception is the 2014 Levothyroxine recall from Mylan Pharmaceuticals. That recall arose from a single FDA order and affected nearly 140,000 bottles.
The companies affected by the 11 biggest recalls are Quality Animal Care, Lloyd Inc. of Iowa, King Legacy, Pfizer, Abbott Laboratories, and Mylan Pharmaceuticals.
Levothyroxine Manufacturers
Thyroxine was first refined at the Mayo Clinic in 1914. It was synthesized in 1927. Levothyroxine Sodium has been a popular generic drug for decades. As such, it’s made by dozens of companies. Below is a short list.
• Lannett Company
• Mylan Pharmaceuticals
• Attix Pharmaceuticals
• King Legacy
• Pfizer
• Alara Pharmaceutical Company
• Virbac
• Lloyd Inc. of Iowa
• Franck’s Lab
• Abbott Laboratories
Full List of All Levothyroxine Recalls
Below is the full list of all 99 Levothyroxine recalls. It includes multiple recall numbers for the major recalls shown above, since each of the big recalls is made up of several different orders.
Class I vs Class II and Class III Recalls
Levothyroxine recalls are classified by their FDA class number between I and III. For reference:
Class I Recalls are urgent, with immediate and significant danger of serious injury or death. None of the recalls listed here are Class I.
Class II Recalls are less serious and imminent than Class I, but they still carry some risk of death or injury were the problem to continue uncorrected. Most of the recalls shown here are Class II.
Class III Recalls carry no risk of death, and are largely in answer to violations of FDA regulations. About 20% of the recalls shown here are Class III.
About the Recall Dates Shown Below
Below, each recall is listed by the date it was classified as either a Class I, II, or III recall. The first bullet point for each event shows the date it was originally issued. If the recall was terminated, that date is given too.
Via: NIH.gov
Also see our Simvastatin recall article here.
2/21/2017 Levothyroxine Recall, Class II
• Recall issued 9/12/2016.
• 135 mcg Levothyroxine Sodium and 15 mcg Liothyronine SR capsule, 90-count bottles.
• Manufacturer: Moore’s Pharmacy Compounding.
• Reason: Incorrect potency.
• 90 capsules recalled.
11/23/2016 Levothyroxine Recall, Class II
• Recall issued 11/7/2016.
• 200 mcg Levoxyl (Levothyroxine Sodium), 100-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Superpotent drug.
• 2,666 bottles recalled.
• Lot # 16H21.
7/21/2016 Levothyroxine Recall, Class II
• Recall issued 1/6/2016.
• 0.5 mg Thyrosyn (Levothyroxine Sodium), 1,000 count bottles.
• Manufacturer: Vedco.
• Reason: Expired and has incorrect expiration date.
• 876 bottles recalled.
• Lot # 140112.
7/6/2016 Levothyroxine Recall, Class II
• Recall issued 3/25/2016, terminated 4/10/2017.
• All T4-levothyroxine Products.
• Compounding company: Reliable Drug and/or Reliable Compounding Pharmacy.
• Reason: Absent processing controls.
• All lots from 3/24/2015 through 3/24/2016.
11/25/2015 Levothyroxine Recall, Class II
• Recall issued 2/6/2015, terminated 10/20/2016.
• 0.1mg Levothyroxine Sodium (Lloyd Thyro-Tabs Canine), 1,000-tablet bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Superpotent drug.
• 761 bottles recalled.
• Lot # VKB12114.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.1 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 11,885 180-count and 2,343 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.2 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 17,036 180-count and 3,664 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.3 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles and 0.3 mg Caninthrox (Levothyroxine Sodium)
• Made for Pala-tech Laboratories and BET Laboratories.
• Reason: Poor manufacturing practices.
• 11,870 180-count and 2,290 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.4 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 14,356 180-count bottles, 2,437 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.5 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 16,125 180-count bottles, 2,752 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.6 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 22,069 180-count bottles, 3,838 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.7 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 12,693 180-count bottles, 1,814 1,000-count bottles recalled.
• All lot codes.
Via: NIH.gov
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.8 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles and 0.8 mg Caninthrox (Levothyroxine Sodium), 1,000-tablet bottles.
• Made for Pala-tech Laboratories and BET Laboratories.
• Reason: Poor manufacturing practices.
• 30,720 180-count bottles, 5,857 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 0.9 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 8,369 180-count bottles, 1,048 1,000-count bottles recalled.
• All lot codes.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• 1.0 mg Levothyroxine Sodium (Canine Thyroid Chewable tablets by Pala-Tech), 180-tablet and 1,000-tablet bottles.
• Made for Pala-tech Laboratories.
• Reason: Poor manufacturing practices.
• 12,621 180-count bottles, 2,248 1,000-count bottles recalled.
• All lot codes.
Save Money on Waste Disposal Now
Medical waste disposal costs go up 18% every nine months. Find out how more and more private practices and clinics have turned that equation on its head with MedPro Disposal. MedPro delivers reliable service at predictable prices. See how much you could be saving here with this handy savings calculator.
5/29/2015 Levothyroxine Recall, Class II
• Recall issued 3/13/2015.
• Levothyroxine Sodium 0.22%, 1 lb and 10 lb containers, packaged as Equine Thyroid Supplement by Pala-Tech and Equine Thyroid Supplement by Equithox.
• Made for Pala-tech Laboratories and BET Laboratories.
• Reason: Poor manufacturing practices.
• 28,027 1-lb and 2,402 10-lb containers recalled.
• All lot codes.
5/27/2015 Levothyroxine Recall, Class II
• Recall issued 5/5/2015.
• 0.2 mg Levothyroxine Sodium (Virbac Animal Health Soloxine), 250 count bottles.
• Manufacturer: Virbac AH.
• Reason: missing label.
• 3,828 250-tablet bottles recalled.
• Lot # 140977.
4/20/2015 Levothyroxine Recall, Class II
• Recall issued 11/14/2014, terminated 10/7/2015.
• Levothyroxine Sodium active ingredient.
• Manufacturer: Attix Pharmaceuticals.
• Reason: Potential for penicillin cross contamination.
• 4,605 grams recalled.
• All lots repackaged/distributed 1/5/12 to 2/12/15.
1/23/2015 Levothyroxine Recall, Class III
• Recall issued 12/22/2014.
• 0.1 mg Levothyroxine Sodium (Virbac Soloxine), 250-count and 1,000-count bottles.
• Manufacturer: Virbac AH.
• Reason: Missing lot numbers and expiration dates, foreign tablet present.
• 1,392 1,000-count and 1,344 250-count bottles recalled.
• Lot # 130846.
1/23/2015 Levothyroxine Recall, Class III
• Recall issued 12/22/2014.
• 0.2 mg Levothyroxine Sodium (Virbac Soloxine), 250-count bottle.
• Manufacturer: Virbac AH.
• Reason: Missing lot numbers and expiration dates.
• 3,156 250-count bottles recalled.
• Lot # 141103.
1/23/2015 Levothyroxine Recall, Class III
• Recall issued 12/22/2014.
• 0.8 mg Levothyroxine Sodium (Virbac Soloxine), 250-count and 1,000-count bottles.
• Manufacturer: Virbac AH.
• Reason: Missing lot numbers and expiration dates.
• 1,200 1,000-count and 3,648 250-count bottles recalled.
• Lot # 130921.
2/10/2014 Levothyroxine Recall, Class II
• Recall issued 1/14/2014, terminated 10/14/2015.
• 200 mcg Levothyroxine Sodium tablets, 100-count bottle.
• Distributor: Mylan Pharmaceuticals.
• Reason: Subpotent drug.
• 138,970 bottles recalled.
• Lot # 3037531, 3038284.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 125 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Magnesium Chloride DR.
• 90 tablets recalled.
• Pedigree AD70633_4.

1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 175 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Cinacacet HCl.
• 90 tablets recalled.
• Pedigree W003743.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 112 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as multivitamin or multimineral.
• 90 tablets recalled.
• Pedigree AD22865_16.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 88 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Nebivolol HCl, Melatonin, Isosorbide Dinitrate, or Hydrocortisone.
• 600 tablets recalled.
• Pedigree AD73652_10, W003047, W003476, W002967, AD42584_1.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 112 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Zinc Sulfate, Hydralazine HCl, or Cholecalciferol.
• 499 tablets recalled.
• Pedigree AD60211_1, AD52778_37, W003847, AD30197_13, AD49423_7.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 175 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Pramipexole Di-HCl.
• 100 tablets recalled.
• Pedigree W003151.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 12.5 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Calcium Acetate, Carbamazepine ER, or Chlorthalidone.
• 600 tablets recalled.
• Pedigree AD30140_40, AD46265_40, AD73525_49.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 88 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Guanfacine HCl.
• 100 tablets recalled.
• Pedigree W003010.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 112 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Raltegravir.
• 100 tablets recalled.
• Pedigree AD60272_22.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 175 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as 88 mcg Levothyroxine Sodium or Hydroxyzine Pamoate.
• 200 tablets recalled.
• Pedigree AD46265_37, W003009.
How Much Money Can You Save on Waste Disposal?
With out-of-control rate hikes from most medical waste disposal companies, it’s no wonder so many private practices and clinics handle their medical waste needs with MedPro Disposal. Predictable rates and reliable service makes MedPro the smart choice for sharps, pharmaceutical waste, biohazard waste, and compliance training. To find out how much you could be saving, see this handy savings calculator.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 137 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Isoniazid.
• 100 tablets recalled.
• Pedigree AD60272_76.
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 88 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Clomipramine HCl, Hydroxychloroquine Sulfate, or Hyoscyamine Sulfate SL.
• 360 tablets recalled.
• Pedigree AD46265_34, AD70629_13, W003439, AD60272_73.
Via: NIH.gov
1/20/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 137 mcg Levothyroxine Sodium tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Omega-3 Fatty Acid.
• 90 tablets recalled.
• Pedigree AD22616_10.
1/16/2014 Levothyroxine Recall, Class II
• Recall issued 7/2/2013, terminated 2/7/2014.
• 19 mcg/4.5 mcg Levothyroxine/ Liothyronine tablet.
• Distributor: Aidapak Services.
• Reason: Possibly mislabeled as Magnesium Gluconate Dihydrate.
• 102 tablets recalled.
• Pedigree AD30197_19.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 50 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 4,440 bottles recalled.
• Lot # 1098751.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 75 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 19,787 bottles recalled.
• Lot # 1098752, 1099890.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 88 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 12,156 bottles recalled.
• Lot # 1098967.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 100 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 142,103 bottles recalled.
• Lot # 1095184, 1095185, 1095186, 1095187, 1096370, 1097547, 1097588, 1097589.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 112 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 40,311 bottles recalled.
• Lot # 1095208, 1097177, 1098537.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 125 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 77,471 bottles recalled.
• Lot # 1095209,1095211, 1097408, 1097731, 1097732.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 137 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 12,911 bottles recalled.
• Lot # 1096372.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 150 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 61,347 bottles recalled.
• Lot # 1095213, 1095214, 1097733, 1098540.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 175 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 32,345 bottles recalled.
• Lot # 1095922, 1097735, 1099892.
5/21/2013 Levothyroxine Recall, Class II
• Recall issued 4/1/2013, terminated 5/8/2014.
• 200 mcg Levothyroxine Sodium tablets (Levothroid), 100 count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 29,489 bottles recalled.
• Lot # 1095923, 1097828.
Via: NIH.gov
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 25 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 51,591 bottles recalled.
• Lot # 65228, 65636, 65180, 65769.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 50 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 195,699 bottles recalled.
• Lot # 64934, 65059, 65179, 65630, 65916, 66367, 66718, 64338, 64932, 65060, 65235, 65853, 65962.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 75 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 194,142 bottles recalled.
• Lot # 64197, 64339, 65061, 65236, 65917, 66122, 66427, 64340, 64933, 65062, 65237, 65238, 66121.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 88 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 112,914 bottles recalled.
• Lot # 64935, 65239, 65900, 66370, 66391, 64927, 65240.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 100 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 195,201 bottles recalled.
• Lot # 64341, Exp 04/1364928, 65064, 65233, 66162, 66365, 66677, 64342, 64929, 65065, 65234, 65539, 65901, 66163.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 112 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 107,236 bottles recalled.
• Lot # 64936, 65634, 66295, 66669, 65063, 65767.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 125 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 103,796 bottles recalled.
• Lot # 64333, 64937, 65629, 66296, 64931, 65766.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 137 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 77,272 bottles recalled.
• Lot # 64190, 64331, 65642, 66297, 64326, 64332, 65771.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 150 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 56,405 bottles recalled.
• Lot # 65066, 65644, 64327, 65772.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 175 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 51,438 bottles recalled.
• Lot # 64329, 65229, 65913, 64330, 65230, 65915.
5/20/2013 Levothyroxine Recall, Class II
• Recall issued 4/30/2013.
• 200 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Subpotent drug.
• 33,227 bottles recalled.
• Lot # 64301, 65628, 64300, 65765.
Are You Paying Too Much for Medical Waste Disposal?
You aren’t if you’re one of MedPro Disposal‘s 200,000+ customers. While most disposal outfits hike their rates up regularly, MedPro keeps a tight reign on prices to keep customers satisfied and loyal. For sharps, biohazard waste, pharmaceutical waste, and compliance training, see why MedPro is the smart choice with this handy savings calculator.
Via: NIH.gov
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.1 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc. of Iowa.
• Reason: Illegible or missing product lot number and/or expiration date.
• 14,439 120-count bottles recalled.
• Lot # VKE29211.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.2 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 12,387 120-count bottles recalled.
• Lot # KB33411, KB33411A.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.3 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 12,387 120-count bottles recalled.
• Lot # KA32111, KA32111A.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.4 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 12,632 120-count bottles recalled.
• Lot # KB33611, KB33611A.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.6 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 15,024 120-count bottles recalled.
• Lot # KA32511.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.5 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 14,669 120-count bottles recalled.
• Lot # VKA31311.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.7 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 10,172 120-count bottles recalled.
• Lot # KD33611, KD33611A.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 0.8 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 23,717 120-count bottles recalled.
• Lot # VKB30711, VKB02412.
5/3/2013 Levothyroxine Recall, Class III
• Recall issued 4/4/2013, terminated 3/26/2014.
• 1.0 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count bottles.
• Manufacturer: Lloyd, Inc.
• Reason: Illegible or missing product lot number and/or expiration date.
• 11,122 120-count bottles recalled.
• Lot # VKF33611, VKF33611A.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 25 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 23,210 bottles recalled.
• Lot # 66675B, 66852B, 67138B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 50 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 29,613 bottles recalled.
• Lot # 66730B, 66853B, 66731B, 67116B, 66856B, 67341B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 75 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 37,809 bottles recalled.
• Lot # 66369B, 66679B, 66850B, 66676B, 66732B, 67136B.
Via: NIH.gov
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 88 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 26,447 bottles recalled.
• Lot # 66619B, 67010B, 66733B, 67441B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 100 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 18,195 bottles recalled.
• Lot # 66897B, 67137B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 112 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 9,213 bottles recalled.
• Lot # 67343B, 66902B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 125 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 37,891 bottles recalled.
• Lot # 66373B, 66851B, 66792B, 67349B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 137 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 7,901 bottles recalled.
• Lot # 67013B, 66900B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 150 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 36,045 bottles recalled.
• Lot # 66375B, 66719B, 66904B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 175 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 10,121 bottles recalled.
• Lot # 67507B, 67508B.
4/18/2013 Levothyroxine Recall, Class II
• Recall issued 3/28/2013.
• 200 mcg Levoxyl (Levothyroxine Sodium) tablets, 100-count and 1,000-count bottles.
• Manufacturer: King Pharmaceuticals.
• Reason: Chemical contamination. Has strong odor.
• 14,464 bottles recalled.
• Lot # 66671B, 67512B, 66739B 67513B.
3/21/2013 Levothyroxine Recall, Class II
• Recall issued 11/15/2012, terminated 7/1/2013.
• 0.175 mg Levothyroxine tablets (Levothyroxine Sodium), 30-count bottles.
• Distributor: Physicians Total Care.
• Reason: Subpotent drug.
• 90 pills recalled.
• Lot # 6WX2.
12/28/2012 Levothyroxine Recall, Class II
• Recall issued 12/4/2012, terminated 7/10/2013.
• 150 mcg Synthroid (Levothyroxine Sodium) tablets, 90 count bottles.
• Manufacturer: Abbott Laboratories.
• Reason: Wrong dosage shown on label.
• 28,524 bottles recalled.
• Lot # 18262A8.
12/21/2012 Levothyroxine Recall, Class II
• Recall issued 7/25/2012, terminated 11/14/2013.
• 50 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufactured for: Forest Pharmaceuticals.
• Reason: Subpotent drug.
• 37,441 100-tablet bottles recalled.
• Lot # 1093992, 1094095.
12/21/2012 Levothyroxine Recall, Class II
• Recall issued 7/25/2012, terminated 11/14/2013.
• 75 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufactured for: Forest Pharmaceuticals.
• Reason: Subpotent drug.
• 16,548 100-tablet bottles recalled.
• Lot # 1094098.
Via: NIH.gov
12/21/2012 Levothyroxine Recall, Class II
• Recall issued 10/29/2012, terminated 1/3/2014.
• 175 mcg Levothyroxine Sodium tablets, 90-count bottles.
• Manufacturer: Patheon Puerto Rico.
• Reason: Subpotent.
• 7,432 bottles recalled.
• Lot # 11T7011A.
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 50 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 13,692 100-tablet bottles recalled.
• Lot #1097830.
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 88 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 31,252 100-tablet bottles recalled.
• Lot #1096369, 092046.
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 112 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 37,827 100-tablet bottles recalled.
• Lot #1096371, 1092299
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 125 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 19,162 100-tablet bottles recalled.
• Lot # 1095210,
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 137 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 36,978 100-tablet bottles recalled.
• Lot # 1095212, 1088877.
12/3/2012 Levothyroxine Recall, Class II
• Recall issued 7/9/2012, terminated 11/14/2013.
• 300 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottles.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Deviations from Current Goods Manufacturing Practices.
• 1,443 100-tablet bottles recalled.
• Lot #1097178.
12/3/2012 Levothyroxine Recall, Class III
• Recall issued 7/27/2012, terminated 3/26/2014.
• 0.2 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count and 1,000-count bottles.
• Manufacturer: Lloyd, Inc. of Iowa.
• Reason: Did not meet product release specs.
• 2,535 120-count and 648 1,000-count bottles recalled.
• Lot # KA16611
12/3/2012 Levothyroxine Recall, Class III
• Recall issued 7/27/2012, terminated 3/26/2014.
• 0.3 mg Levothyroxine sodium tablets, 120-count, 180-count, and 1,000-count bottles, packaged as Lloyd Thyro-Tabs, Animal Health Thyroxine L by Butler Schein, Phoenix Thyrozine, and VEDCO Thyrosyn.
• Manufacturer: Lloyd, Inc. of Iowa.
• Reason: Did not meet specs.
• 1,210 bottles recalled.
• Lot # KB15711, KB13611, KB13611A, KB15711, KB15711A, KB15711, KB15711F, KB13611, KB13611A, KB13611, KB13611A.
12/3/2012 Levothyroxine Recall, Class III
• Recall issued 7/27/2012, terminated 3/26/2014.
• 0.7 mg Levothyroxine sodium tablets in 120-count, 180-count, and 1,000-count bottles. Packaged as Lloyd Thyro-Tabs, Animal Health Thyroxine L by Butler Schein, Phoenix Thyrozine, and VEDCO Thyrosyn.
• Manufacturer: Lloyd, Inc.
• Reason: Did not meet specs.
• 2,300 120-count, 1,517/180-count, and 1,286/1,000-count bottles recalled.
• Lot # KB18011, KB18011 , KB18011A, KB18011, KB18011F, KB18011FA, KB18011, KB18011A.
12/3/2012 Levothyroxine Recall, Class III
• Recall issued 7/27/2012, terminated 3/26/2014.
• 0.8 mg Levothyroxine sodium tablets, 1,000-count bottles. (Packaged as Animal Health Thyroxine L by Butler Schein or VEDCO Thyrosyn)
• Manufacturer: Lloyd, Inc. of Iowa.
• Reason: Did not meet specs.
• 1,891 1,000-count bottles recalled.
• Lot # KD11711, KD11711 , KD11711A.
12/3/2012 Levothyroxine Recall, Class III
• Recall issued 7/27/2012, terminated 3/26/2014.
• 1.0 mg Levothyroxine sodium tablets (Lloyd Thyro-Tabs), 120-count and 1,000-count bottles.
• Manufacturer: Lloyd, Inc. of Iowa.
• Reason: Did not meet specs.
• 4,232 120-count and 811 1,000-count bottles recalled.
• Lot # KB17311.
9/26/2012 Levothyroxine Recall, Class II
• Recall issued 7/19/2012, terminated 11/1/2013.
• 50 mcg Levothyroxine Sodium (Synthroid) tablets, 90-count bottle.
• Manufacturer: Abbott Laboratories
• Reason: Defective container. Thin wall defect.
• 53,448 bottles recalled.
• Lot # 18265A8.
9/26/2012 Levothyroxine Recall, Class II
• Recall issued 7/19/2012, terminated 11/1/2013.
• 75 mcg Levothyroxine Sodium (Synthroid) tablets, 90-count bottle.
• Manufacturer: Abbott Laboratories
• Reason: Defective container. Thin wall defect.
• 42,596 bottles recalled.
• Lot # 18353A8.
9/26/2012 Levothyroxine Recall, Class II
• Recall issued 7/19/2012, terminated 11/1/2013.
• 112 mcg Levothyroxine Sodium (Synthroid) tablets, 90-count bottle.
• Manufacturer: Abbott Laboratories
• Reason: Defective container. Thin wall defect.
• 40,464 bottles recalled.
• Lot # 18355A8.
8/10/2012 Levothyroxine Recall, Class II
• Recall issued 5/21/2012, terminated 8/15/2014.
• .325 MCG/ML Levothyroxine Sodium, injectable 15 ML.
• Manufacturer: Franck’s Lab Inc.
• Possible contamination.
• 2 units recalled.
• Rx # 0370408, 0408889.
6/22/2012 Levothyroxine Recall, Class II
• Recall issued 2/3/2012, terminated 7/30/2013.
• 50 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottle.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Subpotent drug and low assay.
• 19,166 bottles recalled.
• Lot # 1087589.
6/22/2012 Levothyroxine Recall, Class II
• Recall issued 2/24/2012, terminated 7/30/2013.
• 75 mcg Levothyroxine Sodium tablets (Levothroid), 100-count bottle.
• Manufacturer: Lloyd Inc. of Iowa.
• Reason: Subpotent drug and low assay.
• 19,039 bottles recalled.
• Lot # 1092045.
Conclusion
Levothyroxine is a popular thyroid hormone replacement generic that’s been on the market for decades. The drug has seen 99 recalls since 2012. That’s a lot, but the vast majority are really just bundles of FDA recall orders centered around 24 individual incidents. The table at the top of this article shows the major recalls, amounting to over 2.7 million bottles. For the full list of recalls, see the longer list above.
Interested in drug recalls? See our Omeprazole recall post here.
Are You Paying Too Much for Biohazard Waste Disposal?
Unless you’re one of MedPro Disposal’s customers, the answer is almost certainly, “yes.”
MedPro Disposal offers low-cost, secure medical waste disposal with predictable service and predictable cost. Check out our practice savings calculator here to see how much you could save on your medical waste disposal.
Find Out How Much You Can Save Instantly.
Try our on-line savings calculator.
SAVINGS CALCULATOR
© MedPro Waste Disposal, LLC, 2019. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to the author and MedPro Waste Disposal, LLC with appropriate and specific direction to the original content._
________________________________________

The 10 Worst Medications for Your Kidneys

Dr. Sharon Orrange
Dr. Orrange is an Associate Professor of Clinical Medicine in the Division of Geriatric, Hospitalist and General Internal Medicine at the Keck School of Medicine of USC.
Posted on March 7, 2019

Medications that can damage the kidneys are known as “nephrotoxic medications.” These drugs can cause direct damage to the kidneys, and their use accounts for up to 25% of acute kidney injuries. For people with even mild kidney failure, you might want to think twice (or talk to your doctor) before you take these medications.
1) NSAIDS
NSAIDS, or nonsteroidal anti-inflammatory drugs like ibuprofen (Advil, Motrin) and naproxen (Aleve), lead the list for drugs that cause kidney damage because of their widespread use. NSAIDS are used to treat a host of conditions such as fever, rheumatoid arthritis, menstrual pain, and inflammation, but they can also reduce the amount of blood flow to the kidneys, resulting in a higher risk for kidney damage or failure.
People with heart failure, liver disease, or previous kidney problems are at even higher risk when taking NSAIDS. To minimize any kidney damage, try to use these medications sparingly, at their lowest effective dose for the shortest period of time.
2) Vancomycin
Vancomycin is an antibiotic used to treat severe methicillin-resistant Staphylococcus aureus (MRSA) infections that can cause kidney damage and acute interstitial nephritis, or swelling in the kidney, in some patients. If you are taking vancomycin, your doctor should closely monitor your kidneys for any injury.
3) Diuretics
Diuretics, or water pills, are used to treat conditions like high blood pressure, glaucoma, and edema. Popular medications in this class of drugs include hydrochlorothiazide, furosemide, and spironolactone. Many diuretics can lead to worsening kidney function and abnormal electrolyte levels in your blood.
Don't miss out on savings!
Get the best ways to save on your prescriptions delivered to your inbox.

By signing up, I agree to GoodRx's terms of service and privacy policy.
4) Iodinated radiocontrast
Although this sounds like a complicated term, “iodinated radiocontrast” refers to any contrast dyes used in diagnostic testing, such as a CT scan. Iodinated radiocontrast agents are one of the most common causes of kidney injury among hospitalized patients, occurring within 24 to 48 hours after receiving an IV contrast injection.
5) ACE inhibitors
ACE inhibitors can be good and bad for your kidneys. These are medications that tend to end in “-il,” like lisinopril, enalapril, and ramipril. ACE inhibitors are usually used for high blood pressure and heart failure.
Sometimes, ACE inhibitors can cause kidney damage right when you start taking them, and the risk is higher if you are dehydrated. If you have any existing kidney problems, you will likely start on a low dose of ACE inhibitors and your doctor may need you to come in for routine blood creatinine tests to monitor the health of your kidneys.
6) Jardiance
Jardiance is a diabetes medication which has been reported to cause kidney failure. Importantly, Jardiance has diuretic effects and interacts with other nephrotoxic drugs (drugs on this list), raising the risk for toxic kidney effects. Rare, but it can happen.
7) Aminoglycoside antibiotics
Aminoglycoside antibiotics are known for causing kidney injury—even at low doses. People with chronic kidney disease, dehydration, or those who have been taking these antibiotics for a long time are at particularly high risk. The most toxic aminoglycoside is neomycin, followed by gentamicin, tobramycin, and amikacin. [coupond rug=streptomycin]Streptomycin[/coupon] is the least toxic. Although these medications are typically used in hospitals, they are important to keep at the back of your mind!
8) HIV medications and antiviral drugs
Certain antiviral HIV medications are linked to long-term kidney damage and can increase your risk for kidney disease. Viread (tenofovir) and Reyataz (atazanavir) have both been shown to cause acute kidney injury.
9) Zoledronic acid
Zoledronic acid (Zometa, Reclast) is typically used to treat osteoporosis but is a known cause of kidney damage and renal failure. Given as an IV infusion for metastatic bone cancer, Zometa carries a well-established risk of kidney function impairment.
10) Foscarnet
Foscarnet, also given by IV, is a rarely used drug that treats viral infections in patients with weakened immune systems. It is highly toxic to the kidneys.
There you have it! Dr O.

FDA Recalls Thyroid Tablets Made by Chinese Firm
BY JACK PHILLIPS
August 14, 2018 Updated: August 14, 2018
Share

The U.S. Food and Drug Administration (FDA) announced the recall of Westminster Pharmaceuticals thyroid tablets due to the risk of adulteration.
In an Aug. 9 statement, the FDA said that Levothyroxine and Liothyronine 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg thyroid tablets are being recalled as precautionary measures.
They were “manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s import alert” regarding a Chinese firm that made the products, the agency said.
A 2017 inspection of China’s Sichuan Friendly Pharmaceutical Co. drugs discovered “deficiencies” and could “represent the possibility of risk being introduced into the manufacturing process,” the FDA said.
Westminster Pharmaceuticals said it hasn’t received any reports of adverse incidents related to the products.
According to the FDA, “Appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. Thyroid is not associated with serious adverse reactions and does not have a known tumorigenic potential.”
“Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product,” it said.
The products in the recall are in 100-count bottles, and consumers are urged to inspect the product’s NDC’s, product description, lot numbers, and expiration dates, said the FDA. The list of drugs that are subjected to the recall can be found here.
“Westminster is notifying its direct accounts by email and by phone to immediately discontinue distribution of the product being recalled and to notify their sub-wholesale accounts of this product recall and make arrangements for impacted product to be returned to Westminster. Instructions for returning recalled products are given in the Recall Notice Letter and Recall Response Form. Consumers that have these products, which are being recalled should not discontinue use before contacting their physician for further guidance,” the FDA said.
<img class=" wp-image-2609705" src="https://www.theepochtimes.com/assets/uploads/2018/07/20180731-4d245b511c... alt="valsartan recall FDA" width="777" height="437" /> The FDA has expanded its recall of valsartan. (Screenshot/NTD TV)
Defective Drugs
It comes as the FDA expanded its recall of the blood pressure and heart drug valsartan, primarily manufactured by China’s Zhejiang Huahai Pharmaceutical—a major global manufacturer of generic valsartan. The FDA said the drug had been contaminated.
The valsartan recall, as well as the recall of the thyroid pills, highlights how defective medicines and pharmaceutical ingredients made by Chinese firms pose a health danger in the United States.
“There is a lack of trust in medicines made in China now,” Rosemary Gibson, a senior adviser at The Hastings Center, told The Epoch Times in July.
<img class=" wp-image-2588586" src="https://www.theepochtimes.com/assets/uploads/2018/07/10/Apple-News.png" alt="" width="220" height="33" /> Apple, iPhone, and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
“The public wants their medicine to be safe. This carcinogen hidden in valsartan raises the question whether other products that are made in China have been made contrary to the global standard we came to accept,” Gibson said.
In an annual report, the U.S.–China Economic and Security Review Commission said that China is now a “prolific source” of defective and counterfeit drugs in the United States, adding that “Chinese consumers may prefer U.S. pharmaceutical products due to concerns over the quality of domestic drugs.”
“China has been a prolific source of counterfeit and defective medicine. In 2012, Chinese authorities seized 77 million domestically produced gel capsules that were created from industrial waste and contained excessive levels of cadmium,” the commission’s report noted.
Watch Next:
Falun Gong Practitioners Are Being Killed for Organs in China
Before the year 2000, organ transplantation in China was a relatively niche medical treatment.

1. Cadmium (Cd) Toxicity: What Diseases Are Associated with ...
https://www.atsdr.cdc.gov/csem/csem.asp?csem=6&po=12

Cadmium toxicity may cause renal dysfunction with both tubular and glomerular damage with resultant proteinuria. Bone changes appear to be secondary to renal tubular dysfunction. No evidence of teratogenic effects in cadmium-exposed humans has been reported.
o Risk Factors · Where Found · Case Studies

o
2. Cadmium poisoning: Introduction

3. Cadmium poisoning: A type of heavy metal poisoning caused by excessive exposure to cadmium. More detailed information about the symptoms, causes, and treatments of Cadmium poisoning is available below.

Cadmium Toxicity

• Nervous System: Cadmium inhibits release of acetylcholine and activates cholinesterase. This results in a tendency for hyperactivity of the nervous system. Cadmium also directly damages nerve cells.
• Energy: Cadmium causes strong inhibition of essential enzymes in the Krebs energy cycle
• Bones and Joints: Cadmium alters calcium and phosphorus metabolism, thus contributing to arthritis, osteoporosis and neuromuscular diseases. The findings of one study, conducted by the Division of Laboratory Medicine, Department of Toxicology, at the Medical University of Silesia, showed that cadmium has both a direct and indirect toxic effect on bones (3).
• Cardiovascular System: Cadmium replaces zinc in the arteries, contributing to brittle, inflexible arteries.
• Digestive System: Cadmium interferes with production of digestive enzymes that require zinc.
• Reproductive System: In men, low sperm counts, prostate problems and impotence can result from cadmium-induced zinc deficiency. In women, cadmium can cause reduced fertility.
• Endocrine System: Zinc is required for growth and insulin release. Cadmium can contribute to failure to thrive, delayed growth development, and diabetes.
• Excretory System: Cadmium accumulates in the kidneys, resulting in high blood pressure and kidney disease.
• Dental: Alterations in calcium and vitamin D activity, caused by cadmium toxicity, can result in cavities and tooth deformities.
• Psychological: Cadmium toxicity is associated with learning disorders and hyperactivity. This may be due to zinc deficiency, or to inhibition of acetylcholine release in the brain.
• Reproductive Health: Birth defects often are related to cadmium, when it replaces zinc and other metals in vital genetic functions and in the DNA and RNA of the body. This causes defective genetic expression, which is not the same as defective genes.
(7)
• Detox Symptoms

• When cadmium is pushed out of the body, a person may feel tired, moody, emotional, and sometimes very uneasy and vulnerable for a few days. When a large cadmium elimination occurs, one may notice odd smells or tastes, a lot of fatigue and perhaps pain in the kidneys, bones or elsewhere. It usually passes quickly, however.

• Another symptom of cadmium elimination that is a reddish, itchy, burning rash on the face only. It, too, is temporary and passes.

Some of the symptoms associated with cadmium toxicity include (1, 5, 6, 7):
• Abdominal pain
• Aches
• Ages the skin
• Alcoholism
• Alopecia
• Anemia
• Arteriosclerosis
• Arthritis (osteo and rheumatoid)
• Bone disease
• Bone pain in middle of bone(s)
• Cardiovascular disease
• Cavities and tooth deformities
• Cerebral hemorrhage
• Cirrhosis
• Cramps
• Depression
• Diabetes
• Diarrhea
• Digestive disturbances
• Emphysema
• Enlarged heart
• Flu-like symptoms such as chills, muscle weakness, and aches (again, when breathing in cadmium-polluted air)
• Fragile bones
• Growth impairment
• Headaches
• High cholesterol
• High blood pressure
• Hyperkinetic behavior
• Hyperlipidemia
• Hypertension
• Hypoglycemia
• Impaired bone healing
• Impotence
• Inflammation
• Infertility
• Joint pain
• Kidney disease (cadmium is very toxic to the kidneys)
• Learning disorders
• Liver damage
• Lung disease
• Low energy
• Low sperm count
• Lung disease
• Memory loss/brain fog
• Migraines
• Muscle weakness
• Nausea
• Nerve cell damage
• Prostate dysfunction
• Reduced fertility/reproductive disorders
• Shortness of breath
• Smoker’s cough
• Schizophrenia
• Strokes
• Swelling of the nose, pharynx, and larynx (when chronically inhaling cadmium)
• Vomiting

From Katrine Elizabeth sackett 32463 whitelady(5’3)(5’2 ½) 7101 n ih 35 austin texas apt 214
Information can be found under google that is the easiest and fastest way to find it
Date March 14, 2019 time 9:30pm

FDA Recalls Thyroid Tablets Made by Chinese Firm
BY JACK PHILLIPS
August 14, 2018 Updated: August 14, 2018
Share

The U.S. Food and Drug Administration (FDA) announced the recall of Westminster Pharmaceuticals thyroid tablets due to the risk of adulteration.
In an Aug. 9 statement, the FDA said that Levothyroxine and Liothyronine 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg thyroid tablets are being recalled as precautionary measures.
They were “manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s import alert” regarding a Chinese firm that made the products, the agency said.
A 2017 inspection of China’s Sichuan Friendly Pharmaceutical Co. drugs discovered “deficiencies” and could “represent the possibility of risk being introduced into the manufacturing process,” the FDA said.
Westminster Pharmaceuticals said it hasn’t received any reports of adverse incidents related to the products.
According to the FDA, “Appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. Thyroid is not associated with serious adverse reactions and does not have a known tumorigenic potential.”
“Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product,” it said.
The products in the recall are in 100-count bottles, and consumers are urged to inspect the product’s NDC’s, product description, lot numbers, and expiration dates, said the FDA. The list of drugs that are subjected to the recall can be found here.
“Westminster is notifying its direct accounts by email and by phone to immediately discontinue distribution of the product being recalled and to notify their sub-wholesale accounts of this product recall and make arrangements for impacted product to be returned to Westminster. Instructions for returning recalled products are given in the Recall Notice Letter and Recall Response Form. Consumers that have these products, which are being recalled should not discontinue use before contacting their physician for further guidance,” the FDA said.
<img class=" wp-image-2609705" src="https://www.theepochtimes.com/assets/uploads/2018/07/20180731-4d245b511c... alt="valsartan recall FDA" width="777" height="437" /> The FDA has expanded its recall of valsartan. (Screenshot/NTD TV)
Defective Drugs
It comes as the FDA expanded its recall of the blood pressure and heart drug valsartan, primarily manufactured by China’s Zhejiang Huahai Pharmaceutical—a major global manufacturer of generic valsartan. The FDA said the drug had been contaminated.
The valsartan recall, as well as the recall of the thyroid pills, highlights how defective medicines and pharmaceutical ingredients made by Chinese firms pose a health danger in the United States.
“There is a lack of trust in medicines made in China now,” Rosemary Gibson, a senior adviser at The Hastings Center, told The Epoch Times in July.
<img class=" wp-image-2588586" src="https://www.theepochtimes.com/assets/uploads/2018/07/10/Apple-News.png" alt="" width="220" height="33" /> Apple, iPhone, and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
“The public wants their medicine to be safe. This carcinogen hidden in valsartan raises the question whether other products that are made in China have been made contrary to the global standard we came to accept,” Gibson said.
In an annual report, the U.S.–China Economic and Security Review Commission said that China is now a “prolific source” of defective and counterfeit drugs in the United States, adding that “Chinese consumers may prefer U.S. pharmaceutical products due to concerns over the quality of domestic drugs.”
“China has been a prolific source of counterfeit and defective medicine. In 2012, Chinese authorities seized 77 million domestically produced gel capsules that were created from industrial waste and contained excessive levels of cadmium,” the commission’s report noted.
Watch Next:
Falun Gong Practitioners Are Being Killed for Organs in China
Before the year 2000, organ transplantation in China was a relatively niche medical treatment.

1. poisoning
Naturally Occurring Toxic Heavy Metal
Cadmium is a naturally occurring toxic heavy metal with common exposure in industrial workplaces, plant soils, and from smoking. Due to its low permissible exposure in humans, overexposure may occur even in situations where trace quantities of cadmium are found. Cadmium is used extensively in electroplating, although the nature of the operation does not generally lead to overexposure. Cadmium is also found in some industrial paints and may represent a hazard when sprayed. Operations involving removal of cadmium paints by scraping or blasting may pose a significant hazard. The primary use of cadmium is in the manufacturing of NiCd rechargeable batteries. The primary source for cadmium is as a byproduct of refining zinc metal. Exposures to cadmium are addressed in specific standards for the general industry, shipyard employment, the construction industry, and the agricultural industry
From Katrine Elizabeth sackett 32463 whitelady(5’3)(5’2 ½) 7101 n ih 35 austin texas apt 214
Information can be found under google that is the easiest and fastest way to find it
Date March 14, 2019 time 9:30pm

Views: 
689
Post type: 
Author: 
lizabeths